On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law.
All entries for: Neurological Diseases
May 27, 2026
Johnson & Johnson
Layoffs
New Brunswick, NJ
10,000+ employees
New Jersey’s job market is taking another hit, this time from pharma giant Johnson & Johnson, which is parting ways with 56 employees in New Brunswick, according to a Worker Adjustment and Retraining Notification (WARN) Act posting for the state. The layoffs will take effect on August 21.
This is J&J’s first announced workforce reduction of this year, according to a tally by BioSpace. But the pharma has for years been constantly reshaping its business to accommodate the loss of exclusivity of its autoimmune disease powerhouse Stelara—a campaign that has involved cutting back investments in other parts of its business, while putting more money into higher-value areas like cancer.
Other Big Pharma players to recently slash their New Jersey headcounts include Novartis, Bristol Myers Squibb and Novo Nordisk.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
May 22, 2026
AbbVie
Layoffs
North Chicago, IL
10,000+ employees
AbbVie’s operations in Irvine, California, will be 85 employees leaner after July 20, with layoffs projected to take place on that date, according to a Worker Adjustment and Retraining Notification (WARN) Act alert.
The pharma has over 40 open posts available in California, including data science and biologics product development listings. A recent BioSpace report found that AbbVie CEO Robert Michael saw a 76% pay bump, with his total compensation package reaching $32.5 million last year as compared to $18.5 million in 2024.
As per BioSpace’s tally, this is the first time AbbVie has announced layoffs this year.
Disease Area: Dermatology, Gastrointestinal, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
May 15, 2026
Takeda
Layoffs
Tokyo
10,000+ employees
To cut back on costs, Takeda is rolling out a sweeping “transformation program” that will streamline corporate operations and see some 4,500 employees let go in fiscal year 2026, according to an earnings presentation. That number represents less than 10% of total roles globally and does not reflect hiring plans, a company spokesperson told BioSpace in an emailed response on May 13.
“Right now, we have 2,200 open roles globally and we expect to create new jobs throughout the year, which we are prioritizing filling with internal candidates,” the spokesperson said.
The layoffs will look different across the organization and will be phased according to unique business needs and country requirements, according to the spokesperson. They confirmed that the cuts include an estimated 247 roles in Massachusetts and 387 in other states outlined in a March Worker Adjustment and Retraining Notification (WARN) Act notice.
Disease Area: Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
May 12, 2026
C4 Therapeutics, Inc.
Negative Outlook
Watertown, MA
51-200 employees
These changes are expected to reduce overall Medicaid enrollment and access to care. Although the effect on our future product candidates or business is unknown, any decrease in the number of insured patients or reimbursement levels for our products could adversely affect our potential for revenue and our commercial prospects.
Disease Area: Multiple, Neurological Diseases, Oncology
Drug Type: Small Molecule
May 7, 2026
Denali Therapeutics Inc.
Neutral Outlook
South San Francisco, CA
501-1,000 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.
Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
May 7, 2026
Stoke Therapeutics, Inc.
Neutral Outlook
Bedford, MA
201-500 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 7, 2026
Neumora Therapeutics, Inc.
Neutral Outlook
Waltham, Massachusetts,
51-200 employees
For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the biopharmaceutical industry cannot yet be fully determined, it is likely to be significant.
Disease Area: Neurological Diseases, Psychiatry
Drug Type: Biologic, Small Molecule
May 6, 2026
Tenaya Therapeutics, Inc.
Neutral Outlook
South San Francisco, CA
51-200 employees
While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run. The laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future.
Disease Area: Cardiology, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
May 6, 2026
Sarepta Therapeutics
Neutral Outlook
Cambridge, MA
501-1,000 employees
For example, the Inflation Reduction Act (“IRA”), passed in 2022, IRA has had and will likely continue to have a significant impact on the pharmaceutical industry. In 2025, the current presidential administration issued two executive orders with multiple directives aimed at lowering drug prices.
Disease Area: Neurological Diseases, Rare Diseases
Drug Type: Biologic